Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05405114
- Locations
- 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸East Carolina University_Greenville_0, Greenville, North Carolina, United States
🇺🇸Univ Oklahoma HSC_Okla City, Oklahoma City, Oklahoma, United States
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- Conditions
- Sickle Cell AnemiaBeta Thalassemia
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-03-26
- Target Recruit Count
- 40
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
- Conditions
- Sickle Cell Anemia in ChildrenSickle Cell Disease
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Brown University
- Target Recruit Count
- 400
- Registration Number
- NCT05285917
- Locations
- 🇦🇴
Hospital Geral dos Cajueiros, Luanda, Angola
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
- Conditions
- Priapism Due to Sickle Cell Disease
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT05142254
- Locations
- 🇳🇬
Murtala Mohammed Specialist Hospital, Kano, Nigeria
🇳🇬Aminu Kano Teaching Hospital, Kano, Nigeria
Clinical Experience of Thalidomide in Thalassemic Patients
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Children's Hospital Karachi
- Target Recruit Count
- 135
- Registration Number
- NCT05132270
- Locations
- 🇵🇰
Children's Hospital Karachi, Karachi, Sindh, Pakistan
Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: L-Carnitine, 250 Mg Oral Capsule
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 91
- Registration Number
- NCT05081349
- Locations
- 🇪🇬
Safaa A A Khaled, Assiut, Egypt
Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
- Conditions
- AMLHyperleukocytosis
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 46
- Registration Number
- NCT05062278
- Locations
- 🇲🇽
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer, Monterrey, Nuevo Leon, Mexico
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Theravia
- Target Recruit Count
- 28
- Registration Number
- NCT05025072
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
- Conditions
- Moderate and High Risk Myelofibrosis
- Interventions
- Drug: TQ05105 tablets
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05020652
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College, Tianjin, Tianjin, China
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise SpecifiedMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyOther: Questionnaire Administration
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 3
- Registration Number
- NCT05005182
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.